<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>10824448</identifier>
<setSpec>0300-9041</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Gerson, R</dc:author>
<dc:author>Dolengevich, H</dc:author>
<dc:author>Villalobos, A</dc:author>
<dc:author>Serrano, A</dc:author>
<dc:description xml:lang="en">Generically, ovarian cancer represents a group of tumors with diverse biological and clinical behavior. Thus, germinal cells ovarian tumors, in the vast majority of patients are successfully treated utilizing traditional based on cisplatin chemotherapy. Epithelial ovarian cancer, that accounts for 90% of these cases, although sensitive to chemotherapy has not shown satisfactory results. In the search better tumoral response in the treatment of epithelial ovarian cancer new drugs have surged that promise good results, including docetaxel, topotecan and gemcitabine, both as single agents, or in combination with other therapies utilizing monoclonal antibodies.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2000 Apr </dc:date>
<dc:title xml:lang="es">Quimioterapia en c√°ncer germinal y epitelio de ovario.</dc:title>
<dc:title xml:lang="en">[Chemotherapy in germinal and epithelial ovarian cancer].</dc:title>
<dc:publisher>Ginecologia y obstetricia de Mexico</dc:publisher>
</metadata>
</record>
</pubmed-document>
